WHO releases new guide on developing national programmes for age-friendly cities and communities As population ageing and urbanization rapidly progress worldwide, making our cities and communities more age-friendly is crucial…
A research team led by the National Cancer Centre Singapore (NCCS) with members from Duke-NUS Medical School, KK Women and Children’s Hospital, A*STAR’s Singapore Immunology Network (SIgN), the University of…
WHO releases first-ever Standard on universal access to rapid TB diagnostics The World Health Organization (WHO) has just released for the first-time – the WHO standard: Universal access to rapid tuberculosis…
Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a…
WHO/UNICEF have started the Immunization Annual Data Collection Process We are pleased to announce that the World Health Organization (WHO) / United Nations Children’s Fund (UNICEF) electronic Joint Reporting Form…
Glioblastoma is the most common type of brain tumor in adults. The disease is 100% fatal and there are no cures, making it the most aggressive type of cancer. Such…
CycPeptMPDB, a novel database – created by Tokyo Tech researchers – focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds.…
How to determine the most effective treatment for colon cancer? The response to chemotherapy varies greatly from one patient to another. A team from the UNIGE has developed a new…
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to…
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental…
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under…
Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood…